Company Name: Dimension Therapeutics Inc.  

Dimension Therapeutics Inc. develops therapeutics for rare diseases associated with the liver. The company has several programs that it is advancing toward clinical development, which include treatment candidates for:

  • Glycogen storage disease type Ia (GSDIa)
  • Hemophilia A (collaboration with Bayer HealthCare)
  • Hemophilia B
  • Ornithine transcarbamylase (OTC) deficiency

Ticker Symbol: DMTX (NASDAQ)

Company Website: www.dimensiontx.com

Social Media:

Dimension Therapeutics LinkedIn

Dimension Therapeutics Twitter

Headquarters: Cambridge, MA